M
US self-pay prices

MEDVi GLP-1 prices

Compounding

Compounded semaglutide and tirzepatide programs with the physician review and medication in one price, plus brand-name Wegovy and Zepbound through a separate membership. MEDVi has 2 sourced self-pay GLP-1 offers here. Advertised entry prices: Compounded semaglutide $299/mo; Compounded tirzepatide $299/mo. Compounded products are not FDA-approved. Plan terms, fees and the check date are listed with each quote.

2 offers · US self-pay · 0 maintenance quotes

  • Compounded semaglutide via MEDVi

    Semaglutide · Compounded

    Compounded · Not FDA-approved
    Advertised price$299/mo

    Supply period unverified; excluded from cost ranking.

    Checked

    Maintenance price

    No separate dose price verified

    View offer
    Price conditions & source

    Advertised price: refill price after a $179 first month; physician review, personalized plan, guidance and the medication included; no contract

    Weekly injection. Another MEDVi landing page shows semaglutide at $116 a month in one place and $166 a month in its FAQ. MEDVi also sells a daily GLP-1 tablet from $249 without naming the drug. Compounded; not FDA-approved.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.

    Read the advertised-price source
  • Compounded tirzepatide via MEDVi

    Tirzepatide · Compounded

    Compounded · Not FDA-approved
    Advertised price$299/mo

    Supply period unverified; excluded from cost ranking.

    Checked

    Maintenance price

    No separate dose price verified

    View offer
    Price conditions & source

    Advertised price: monthly plan, a 4-week supply, $199 the first month with a code the page applies itself; $193/mo on 12 weeks, $183 on 24 weeks, $166 on 48 weeks; same price at every dose; auto-renewing subscription

    Weekly injection. Another MEDVi landing page shows tirzepatide at $166 a month, and $199 a month in its FAQ. Multi-month packages are not refunded for unused months. Compounded; not FDA-approved.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.

    Read the advertised-price source

Read prices in context. Compare the same product, dose, and payment terms. A prepaid monthly rate is not a monthly payment. Cost order uses current, recently checked quotes with documented supply periods, converted to 30 days. Other prices are unranked references. Dose changes, introductory terms and added fees affect what you pay.

Missing prices are not estimated. A listed maintenance dose is not a dosing recommendation.

The FDA declared the tirzepatide (December 2024) and semaglutide (February 2025) shortages resolved, ending the exemption that let pharmacies mass-produce compounded copies, and the 503A/503B enforcement-discretion grace periods ended in 2025. The FDA is now actively enforcing (warning letters and takedowns, including a September 2026 warning letter to Empower Pharmacy, a large compounder, over products it called essentially copies of approved semaglutide and tirzepatide), and in 2026 proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list (the public comment period, extended 30 days, closed July 30, 2026; a final decision is pending). Liraglutide is different: it is still on the FDA drug shortage list (brand Victoza and Saxenda in limited supply, generics available, as of September 2026). Compounded GLP-1s are not FDA-approved and are now generally limited to narrow, patient-specific 503A prescriptions, so broad low-cost availability has largely wound down. They also carry safety risks the branded products do not: FDA adverse-event reports, at least one sterility recall (ProRx, October 2025), and counterfeit product found in the US supply chain, so a low price is not a low-risk signal. Prices and availability below may lag these changes; confirm current terms with the provider.

Questions

MEDVi GLP-1 cost: common questions

How much does semaglutide cost through MEDVi?

Compounded semaglutide: $299/mo (refill price after a $179 first month; physician review, personalized plan, guidance and the medication included; no contract). Checked Oct 17, 2026; each quote links its source in the table. Compounded semaglutide is not an FDA-approved product.

How much does tirzepatide cost through MEDVi?

Compounded tirzepatide: $299/mo (monthly plan, a 4-week supply, $199 the first month with a code the page applies itself; $193/mo on 12 weeks, $183 on 24 weeks, $166 on 48 weeks; same price at every dose; auto-renewing subscription). Checked Oct 17, 2026; each quote links its source in the table. Compounded tirzepatide is not an FDA-approved product.

Does MEDVi offer FDA-approved GLP-1 medication or compounded versions?

The MEDVi offers tracked here are compounded: Compounded semaglutide; Compounded tirzepatide. Compounded GLP-1s are not FDA-approved products and are not reviewed by the FDA for safety, effectiveness, or quality.

When were MEDVi prices last checked?

Each quote carries its own check date and links the page it was read from: Oct 17, 2026 for the offers here. A quote not rechecked within 21 days is kept as a dated reference and is no longer stated as a current price.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.